Peregrine Pharmaceuticals Inc (PPHM) 1.28 $PPHM
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.28 (+0.03)
Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma
Marketwired - Mon Feb 09, 7:31AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), ACAD: 34.21 (+0.37), HALO: 14.73 (+0.23), PPHM: 1.28 (+0.03)
Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium
Marketwired - Fri Jan 16, 8:30AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This conference is being held January 15-17, 2015 at the Moscone West Convention Center in San Francisco, California.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Stock to Watch: Peregrine Pharmaceuticals Up 6.4% (PPHM)
Comtex SmarTrend(R) - Thu Jan 08, 10:35AM CST
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's best performing low-priced stocks, up 6.4% to $1.49 on 3.6x average daily volume. Peregrine Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 759,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 1.6%) and outperformed the S&P 500 (6.4% to the S&P's 1.6%) during today's trading.
PPHM: 1.28 (+0.03)
This Potentially Game-Changing Experimental Drug Could Make or Break Peregrine Pharmaceuticals
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 05, 7:03AM CST
Shares of small-cap biopharmaceutical company Peregrine Pharmaceuticals are relatively unchanged for the year, but that doesn't mean things haven't been incredibly volatile for this predominantly clinical-stage company. Peregrine's wild ride ...
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals Down 6.1%, Shares Slide into the Red (PPHM)
Comtex SmarTrend(R) - Mon Dec 15, 12:42PM CST
Peregrine Pharmaceuticals (NASDAQ PHM) is one of today's worst performing low-priced stocks, down 6.1% to $1.39 on 1.0x average daily volume. Peregrine Pharmaceuticals has traded 700,000 shares thus far today, vs. average volume of 696,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's -0.5%) and underperformed the S&P 500 (-6.1% to the S&P's -0.4%) during today's trading.
PPHM: 1.28 (+0.03)
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Marketwired - Fri Dec 12, 7:00AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine Pharma FQ2 results
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 5:47AM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Dec 11, 3:39AM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Dec 10, 3:25PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:04PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwired - Wed Dec 10, 3:02PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, today announced financial results for the second quarter of fiscal year (FY) 2015 ended October 31, 2014. The company also provided an update on its advancing clinical pipeline and reviewed other corporate developments.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Marketwired - Wed Dec 10, 7:06AM CST
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Wed Dec 10, 6:11AM CST
The board of directors of Peregrine Pharmaceuticals (NASDAQ PHM) (NASDAQ PHMP), a biopharmaceutical company, declared on Tuesday its quarterly dividend of USD0.65625 per share of its 10.50% Series E convertible preferred stock.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:35PM CST
SIGM: 6.69 (-0.19), RH: 86.77 (-1.55), MW: 50.88 (+0.73), IRET: 7.75 (+0.09), CENT: 9.00 (-0.08), AVNW: 1.19 (+0.08), WTSL: 0.03 (unch), PPHM: 1.28 (+0.03), CASY: 88.93 (-1.10), SURG: 4.44 (-0.02)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwired - Tue Dec 09, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:26PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Marketwired - Wed Dec 03, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time (4:30 PM Eastern Standard Time). Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.28 (+0.03)
Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma
Marketwired - Mon Feb 09, 7:31AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), ACAD: 34.21 (+0.37), HALO: 14.73 (+0.23), PPHM: 1.28 (+0.03)
Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium
Marketwired - Fri Jan 16, 8:30AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This conference is being held January 15-17, 2015 at the Moscone West Convention Center in San Francisco, California.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Stock to Watch: Peregrine Pharmaceuticals Up 6.4% (PPHM)
Comtex SmarTrend(R) - Thu Jan 08, 10:35AM CST
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's best performing low-priced stocks, up 6.4% to $1.49 on 3.6x average daily volume. Peregrine Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 759,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 1.6%) and outperformed the S&P 500 (6.4% to the S&P's 1.6%) during today's trading. PPHM: 1.28 (+0.03)
This Potentially Game-Changing Experimental Drug Could Make or Break Peregrine Pharmaceuticals
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 05, 7:03AM CST
Shares of small-cap biopharmaceutical company Peregrine Pharmaceuticals are relatively unchanged for the year, but that doesn't mean things haven't been incredibly volatile for this predominantly clinical-stage company. Peregrine's wild ride ...
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals Down 6.1%, Shares Slide into the Red (PPHM)
Comtex SmarTrend(R) - Mon Dec 15, 12:42PM CST
Peregrine Pharmaceuticals (NASDAQ
PHM) is one of today's worst performing low-priced stocks, down 6.1% to $1.39 on 1.0x average daily volume. Peregrine Pharmaceuticals has traded 700,000 shares thus far today, vs. average volume of 696,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's -0.5%) and underperformed the S&P 500 (-6.1% to the S&P's -0.4%) during today's trading. PPHM: 1.28 (+0.03)
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Marketwired - Fri Dec 12, 7:00AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine Pharma FQ2 results
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 5:47AM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Dec 11, 3:39AM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Dec 10, 3:25PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:04PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwired - Wed Dec 10, 3:02PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, today announced financial results for the second quarter of fiscal year (FY) 2015 ended October 31, 2014. The company also provided an update on its advancing clinical pipeline and reviewed other corporate developments.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Marketwired - Wed Dec 10, 7:06AM CST
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Wed Dec 10, 6:11AM CST
The board of directors of Peregrine Pharmaceuticals (NASDAQ
PHM) (NASDAQ PHMP), a biopharmaceutical company, declared on Tuesday its quarterly dividend of USD0.65625 per share of its 10.50% Series E convertible preferred stock. PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:35PM CST
SIGM: 6.69 (-0.19), RH: 86.77 (-1.55), MW: 50.88 (+0.73), IRET: 7.75 (+0.09), CENT: 9.00 (-0.08), AVNW: 1.19 (+0.08), WTSL: 0.03 (unch), PPHM: 1.28 (+0.03), CASY: 88.93 (-1.10), SURG: 4.44 (-0.02)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwired - Tue Dec 09, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
. PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
Peregrine reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:26PM CST
PPHM: 1.28 (+0.03)
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Marketwired - Wed Dec 03, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time (4:30 PM Eastern Standard Time). Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
PPHMP: 19.65 (+0.65), PPHM: 1.28 (+0.03)
